TY  - JOUR

T1  - A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa

JO  - Annals of Oncology

PY  - 2014/09/01

AU  - Ferraldeschi R

AU  - Slovin S

AU  - Hussain S

AU  - Saad F

AU  - Garcia J

AU  - Kabbinavar FF

AU  - Uppal N

AU  - Vogelzang NJ

AU  - Poiesz BJ

AU  - Gelmann E

AU  - Picus J et al

ED  - 

DO  - DOI: 10.1093/annonc/mdu336.24

VL  - 25

SP  - iv267

Y2  - 2024/12/22

ER  -